Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT : a prospective study of 59 patients with neuroendocrine tumors. / Johnbeck, Camilla Bardram; Knigge, Ulrich; Loft, Annika; Berthelsen, Anne Kiil; Mortensen, Jann; Oturai, Peter; Langer, Seppo; Elema, Dennis; Kjaer, Andreas.
I: The Journal of Nuclear Medicine, Bind 58, Nr. 3, 03.2017, s. 451-457.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT
T2 - a prospective study of 59 patients with neuroendocrine tumors
AU - Johnbeck, Camilla Bardram
AU - Knigge, Ulrich
AU - Loft, Annika
AU - Berthelsen, Anne Kiil
AU - Mortensen, Jann
AU - Oturai, Peter
AU - Langer, Seppo
AU - Elema, Dennis
AU - Kjaer, Andreas
N1 - Copyright © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2017/3
Y1 - 2017/3
N2 - Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up and treatment planning of neuroendocrine tumor (NET) patients. Positron emission tomography (PET) based tracers using (68)Ga as the radioisotope have in most centers replaced single-photon emission tomography (SPECT) based tracers as the gold standard. (64)Cu-DOTATATE is a new PET tracer that has been shown to be far superior compared to the SPECT tracer (111)In-DTPA-octreotide. Due to advantages of (64)Cu compared to (68)Ga, we hypothesize that the tracer could have a higher sensitivity than (68)Ga-based tracers. To test this hypothesis, we compared on a head-to-head basis the diagnostic performance of (64)Cu-DOTATATE with that of (68)Ga -DOTATOC in NET patients.METHODS: Fifty-nine NET patients were scanned both with (64)Cu-DOTATATE and (68)Ga-DOTATOC PET and computed tomography (CT) and compared on a head-to-head basis. Discordant lesions were verified during at least 30 months of follow-up.RESULTS: A total of 701 lesions were concordantly detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans while an additional 68 lesions were found by only one of the scans. (64)Cu-DOTATATE showed 42 lesions not found on (68)Ga-DOTATOC of which 33 were found to be true positive on follow up. (68)Ga-DOTATOC showed 26 lesions not found on (64)Cu-DOTATATE of which 7 were found to be true positive on follow up. False positives were mainly lymph node lesions. Accordingly, 83% of the additional true lesions only found on one of the scans were found by (64)Cu-DOTATATE. On a patient-basis additional true lesions were found by (64)Cu-DOTATATE and (68)Ga-DOTATOC in 13 and 3 patients, respectively. All patients with additional lesions also had concordant lesions found by both scans.CONCLUSION: (64)Cu-DOTATATE possesses advantages in the detection of lesions in NET patients compared to (68)Ga-DOTATOC. Although patient based sensitivity was the same for (64)Cu-DOTATATE and (68)Ga-DOTATOC in this cohort, significant more lesions were detected by (64)Cu-DOTATATE. Furthermore, the shelf life of more than 24 hours and the scan window of at least 3 hours make (64)Cu-DOTATATE very favorable and easy to use in the clinical setting.
AB - Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up and treatment planning of neuroendocrine tumor (NET) patients. Positron emission tomography (PET) based tracers using (68)Ga as the radioisotope have in most centers replaced single-photon emission tomography (SPECT) based tracers as the gold standard. (64)Cu-DOTATATE is a new PET tracer that has been shown to be far superior compared to the SPECT tracer (111)In-DTPA-octreotide. Due to advantages of (64)Cu compared to (68)Ga, we hypothesize that the tracer could have a higher sensitivity than (68)Ga-based tracers. To test this hypothesis, we compared on a head-to-head basis the diagnostic performance of (64)Cu-DOTATATE with that of (68)Ga -DOTATOC in NET patients.METHODS: Fifty-nine NET patients were scanned both with (64)Cu-DOTATATE and (68)Ga-DOTATOC PET and computed tomography (CT) and compared on a head-to-head basis. Discordant lesions were verified during at least 30 months of follow-up.RESULTS: A total of 701 lesions were concordantly detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans while an additional 68 lesions were found by only one of the scans. (64)Cu-DOTATATE showed 42 lesions not found on (68)Ga-DOTATOC of which 33 were found to be true positive on follow up. (68)Ga-DOTATOC showed 26 lesions not found on (64)Cu-DOTATATE of which 7 were found to be true positive on follow up. False positives were mainly lymph node lesions. Accordingly, 83% of the additional true lesions only found on one of the scans were found by (64)Cu-DOTATATE. On a patient-basis additional true lesions were found by (64)Cu-DOTATATE and (68)Ga-DOTATOC in 13 and 3 patients, respectively. All patients with additional lesions also had concordant lesions found by both scans.CONCLUSION: (64)Cu-DOTATATE possesses advantages in the detection of lesions in NET patients compared to (68)Ga-DOTATOC. Although patient based sensitivity was the same for (64)Cu-DOTATATE and (68)Ga-DOTATOC in this cohort, significant more lesions were detected by (64)Cu-DOTATATE. Furthermore, the shelf life of more than 24 hours and the scan window of at least 3 hours make (64)Cu-DOTATATE very favorable and easy to use in the clinical setting.
U2 - 10.2967/jnumed.116.180430
DO - 10.2967/jnumed.116.180430
M3 - Journal article
C2 - 27660147
VL - 58
SP - 451
EP - 457
JO - The Journal of Nuclear Medicine
JF - The Journal of Nuclear Medicine
SN - 0161-5505
IS - 3
ER -
ID: 173478217